Alemtuzumab: What is the secret to safe therapy?

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 5, 2011, Pages 364-373

  Elter, Thomas ^a   Hallek, Michael ^a   Montillo, Marco ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia; Fludarabine; Minimal residual disease; Monoclonal antibody

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB; VALACICLOVIR; VALGANCICLOVIR;

ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ESCHERICHIA COLI INFECTION; FEVER; HEART FAILURE; HERPES ZOSTER; HUMAN; INFECTION; INFECTION RATE; INJECTION SITE REACTION; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NOCARDIOSIS; OPPORTUNISTIC INFECTION; PNEUMONIA; PRACTICE GUIDELINE; PSEUDOMONAS PNEUMONIA; PYREXIA IDIOPATHICA; RASH; RIGOR; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 79959840618     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Hallek M. State-of-the-art treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2009;440-449.
2. Campath (alemtuzumab) full prescribing information. Cambridge, MA: Genzyme Corporation; 2009.
3. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554-3561.
4. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5616-5623.
5. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005;23:7024-7031.
6. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 2002;99:2245-2247.
7. Keating M, Coutre S, Rai K, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma. 2004;4:220-227.
8. Osterborg A, Foa R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia. 2009;23:1980-1988.
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma (version 3). Accessed October 14, 2009.
10. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997;15:1567-1574.
11. Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003;98:773-778.
12. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278-3281.
13. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009;27:3994-4001.
14. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891-3897.
15. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23:2971-2979.
16. Cortelezzi A, Pasquini MC, Sarina B, et al. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with chemotherapy-refractory chronic lymphocytic leukemia. Haematologica. 2005;90:410-412.
17. Cortelezzi A, Pasquini MC, Gardellini A, et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia. 2009;23:2027-2033.
18. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768-773.
19. Mone AP, Cheney C, Banks AL, et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia. 2006;20:272-279.
20. Xia MQ, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol. 1993;30: 1089-1096.
21. Smolewski P, Szmigielska-Kaplon A, Cebula B, et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2005;46: 87-100.
22. Flowers C, Rosenthal H, Brown J, et al. Analysis of minimal residual disease from the phase 2 multicenter study of subcutaneous alemtuzumab combined with fludarabine for treatment of relapsed/refractory B-cell chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts). 2007;110:Abstract 3111.
23. Engert A, Gercheva L, Robak T, et al. Improved progression-free survival (PFS) of alemtuzumab (CampathR, MabCampathR) plus fludarabine (FludaraR) versus fludarabine alone as second-line treatment of patients with B-cell chronic lymphocytic leukemia: preliminary results from a phase III randomized trial. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 537.
24. Montillo M, Miqueleiz S, Tedeschi A, et al. Combined fludarabine, cyclophosphamide, and alemtuzumab (FCC), an active regimen for treated patients with chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts). 2007;110:Abstract 3133.
25. Elter T, James R, Stilgenbauer S, Ritgen M, Hallek M, Engert A. Chemoimmunotherapy with fludarabine, cyclophosphamide and alemtuzumab in patients with relapsed/refractory CLL: interim analysis of the CLL2L trial of the German CLL Study Group. Blood (ASH Annual Meeting Abstracts). 2008;112:Abstract 3170 and presented poster.
26. Elter T, James R, Stilgenbauer S, et al. Chemoimmuno-therapy with fludarabine, cyclophosphamide and alemtuzumab (FC-Cam) in patients with relapsed or genetic high-risk CLL: final analysis of the CLL2L trial of the German CLL Study Group. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 209.
27. Wierda WG, O'Brien S, Faderl S, et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood (ASH Annual Meeting Abstracts). 2006; 108:Abstract 31.
28. Wierda WG, O'Brien S, Ferrajoli A, et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk patients with CLL. Blood (ASH Annual Meeting Abstracts). 2007;110:Abstract 628.
29. Lepretre S, Aurran T, Mahe B, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the "Groupe Ouest-est d'Etudes Des Leucemies Aigues et Autres Maladies du Sang" (GOELAMS): CLL2007FMP (for fit medically patients). Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 538.
30. HOVON Web site. HOVON 68 protocol. A randomized phase III study in previously untreated patients with biological high-risk CLL: fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab. http://www.hovon.nl/trials/trials-by-type/cll.html?action=showstudie &studie_id=6&categorie_id=8. Accessed April 4, 2010.
31. Polish Lymphoma Research Group Web site. Geisler C. HOVON68 CLL protocol: annual safety report 2008. http://www.plrg.pl/images/stories/badania/hovon/HOVON68CLL_Annual_Safety_ Report_2008.pdf. Accessed April 4, 2010.
32. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003;101:3413-3415.
33. Faderl S, Ferrajoli A, Wierda W, et al. Continuous infusion/subcutaneous alemtuzumab (Campath-1H) plus rituximab is active for patients with relapsed/ refractory chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts). 2005;106:Abstract 2963.
34. Nabhan C, Patton D, Gordon LI, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2004;45:2269-2273.
35. Frankfurt O, Hamilton E, Acharya S, Duffey S, Raji A, Rosen ST. A phase II trial of alemtuzumab and rituximab in patients with previously untreated CLL. Blood (ASH Annual Meeting Abstracts). 2007;110:Abstract 2056.
36. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer. 2008;113: 2110-2118.
37. Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004;18:1093-1101.
38. Schweighofer CD, Ritgen M, Eichhorst BF, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol. 2009;144: 95-98.
39. Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol. 2006;24:2337-2342.
40. Byrd JC, Peterson BL, Rai KR, et al. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma. 2009;50: 1589-1596.
41. Lin TS, Donohue KA, Lucas MS, et al. Consolidation therapy with subcutaneous alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response after fludarabine and rituximab induction therapy: interim safety analysis of the CALGB Study 10101. Blood (ASH Annual Meeting Abstracts). 2007;110:Abstract 755.
42. Lin TS, Donohue KA, Byrd JC, et al. Consolidation therapy with subcutaneous (SC) alemtuzumab after fludarabine and rituximab (FR) induction therapy improves the complete response (CR) rate in chronic lymphocytic leukemia (CLL) and eradicates minimal residual disease (MRD) but is associated with severe infectious toxicity: final analysis of CALGB study 10101. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 210.
43. Mould DR, Baumann A, Kuhlmann J, et al. Population pharmacokineticspharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol. 2007;64:278-291.
44. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood. 2004;104: 948-955.
45. O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma. 2006;7:125-130.